Shots:
- Prime Therapeutics launches MedDrive in multiple phases and provide a solution to help Blue Plan clients for greater biosimilar adoption and drug cost-saving strategies
- Prime helps the Blue Plan clients through a 100% transparent, unbiased PBM model that serves nearly 33M members across 23 Blue Plans
- Prime and Blue Cross plans to improve the use of biosimilars and other lower cost for effective treatment and to deliver improved affordability without compromising patient outcomes
Click here to read full press release/ article | Ref: Prime Therapeutics | Image: Prime Therapeutics
The post Prime Therapeutics Launches MedDrive for Greater Biosimilar Drug Adoption first appeared on PharmaShots.
